CCL18 and neoplasm: The comprehensive TME and immune landscape analyses allow us to identify the chemokine CCL18 (Chemokine C–C motif ligand 18) derived from TAMs, which could promote tumor cell proliferation and lead to poor prognosis of ESCC.